DehydraTECH-liraglutide / Lexaria Biosci - LARVOL DELTA

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide (ACCESSWIRE) - "Lexaria Bioscience...announces that it has made a strategic business decision to further investigate the commercial opportunities and applications for a unique new GLP-1 solution: orally taken liraglutide processed with our wholly-owned DehydraTECH enhancement technology...As part of that strategic business decision, Lexaria has already filed certain patent applications related to DehydraTECH-enhanced oral liraglutide which, if granted, will further support Lexaria's ability to commercialize oral DehydraTECH-liraglutide...To support the broader strategy of entering the GLP-1 weight loss and diabetes control market as quickly as possible, Lexaria is also preparing to commence pilot clinical testing of DehydraTECH-liraglutide in humans, as announced on January 15, 2025, when we received the necessary independent ethics board approval that allowed our contract research organization to begin to implement and execute human pilot study GLP-1-H25-5 (the 'Study')."

Commercial • New trial • Diabetes • Obesity